Clinical Trials Logo

Clinical Trial Summary

Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine


Clinical Trial Description

This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1) phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04807816
Study type Interventional
Source Institut Bergonié
Contact Antoine ITALIANO, MD, PhD
Phone (0)5.56.33.33.33
Email a.italiano@bordeaux.unicancer.fr
Status Recruiting
Phase Phase 2
Start date February 9, 2022
Completion date April 2026